Synklino
synklino.comLocations
Lyngby, Denmark
industry
Biotechnology · DeepTech · Health
Size
11-50 employees
Stage
Series A
founded in
2017
Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
Something looks off?Open jobs at Synklino
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.